Chemotherapy Induced Anemia - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 51 pages report, published by Global Markets Direct

Keywords : Chemotherapy Induced Anemia Therapeutic Products under Development, Key Players in Chemotherapy Induced Anemia Therapeutics, Chemotherapy Induced Anemia Pipeline Overview, Chemotherapy Induced Anemia Pipeline, Chemotherapy Induced Anemia Pipeline Assessment

Report ThumbnailSeptember-2013
Chemotherapy Induced Anemia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia. Chemotherapy Induced Anemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Anemia.
- A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Induced Anemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Chemotherapy Induced Anemia, H2 2013 8
  • Products under Development for Chemotherapy Induced Anemia - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Discovery and Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 22
  • Assessment by Route of Administration, H2 2013 23
  • Assessment by Stage and Route of Administration, H2 2013 24
  • Assessment by Molecule Type, H2 2013 25
  • Assessment by Stage and Molecule Type, H2 2013 26
  • List of Tables
  • Number of Products Under Development for Chemotherapy Induced Anemia, H2 2013 8
  • Products under Development for Chemotherapy Induced Anemia - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • Eli Lilly and Company, H2 2013 16
  • Reliance Life Sciences Pvt. Ltd., H2 2013 17
  • 3SBio Inc., H2 2013 18
  • ProMetic Life Sciences Inc., H2 2013 19
  • Avesthagen Limited, H2 2013 20
  • Therapure Biopharma Inc., H2 2013 21
  • Assessment by Monotherapy Products, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 26
  • Chemotherapy Induced Anemia Therapeutics - Drug Profile Updates 40
  • Chemotherapy Induced Anemia Therapeutics - Discontinued Products 42
  • Chemotherapy Induced Anemia Therapeutics - Dormant Products 43
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Chemotherapy Induced Anemia Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Chemotherapy Induced Anemia 8
  • Chemotherapy Induced Anemia Therapeutics under Development by Companies 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Discovery and Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Chemotherapy Induced Anemia Therapeutics - Products under Development by Companies 15
  • Companies Involved in Chemotherapy Induced Anemia Therapeutics Development 16
  • Eli Lilly and Company 16
  • Reliance Life Sciences Pvt. Ltd. 17
  • 3SBio Inc. 18
  • ProMetic Life Sciences Inc. 19
  • Avesthagen Limited 20
  • Therapure Biopharma Inc. 21
  • Chemotherapy Induced Anemia - Therapeutics Assessment 22
  • Assessment by Monotherapy Products 22
  • Assessment by Route of Administration 23
  • Assessment by Molecule Type 25
  • Drug Profiles 27
  • NuPIAO - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • epoetin alfa - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • PBI-1402 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • darbepoetin alfa biosimilar - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • LY-2787106 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • PanCyte - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • epoetin - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • TBI-304 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • TP-0413 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • Drug For Chemotherapy Induced Anemia - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • Drug For Chemotherapy Induced Anemia - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • Chemotherapy Induced Anemia Therapeutics - Drug Profile Updates 40
  • Chemotherapy Induced Anemia Therapeutics - Discontinued Products 42
  • Chemotherapy Induced Anemia Therapeutics - Dormant Products 43
  • Chemotherapy Induced Anemia - Product Development Milestones 44
  • Featured News & Press Releases 44
  • Jan 03, 2013: Affymax And Takeda Pharma Announce Permanent J-Code For Omontys Injection Is In Effect 44
  • Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 44
  • Jan 31, 2012: Kyowa Hakko Kirin Withdraws Domestic Application For Additional Chemotherapy-Induced Anemia Indication For NESP 45
  • Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 45
  • Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 45
  • Jul 11, 2011: 3SBio Receives SFDA Approval For High-Dose EPIAO 46
  • Jun 02, 2011: Acceleron And Celgene Initiate Phase II/III Study Of ACE-011 To Treat Chemotherapy-Induced Anemia In Patients With Lung Cancer 47
  • Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 48
  • Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 48
  • Jun 06, 2010: Alder's ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia In Phase IIa Clinical Trial In NSCLC Patients 48
  • Appendix 50
  • Methodology 50
  • Coverage 50
  • Secondary Research 50
  • Primary Research 50
  • Expert Panel Validation 50
  • Contact Us 51
  • Disclaimer 51

Please select a license type

Share

Related Products

Global Markets DirectChemotherapy Induced Anemia - Pipeline Review, H2 2013Product ThumbnailChemotherapy Induced Anemia - Pipeline Review, H2 2013, Industry ReportProduct #: 113323
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved